TRVI News and Press, Trevi Therapeutics Inc. From 10/21/20

Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment Milestone NEW HAVEN, Conn., Oct. ...

NEW HAVEN, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced th...

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced t...

Trevi Therapeutics, Inc. (TRVI) Q2 2020 Earnings Conference Call August 13, 2020 04:30 PM ET Company Participants Jennifer Good - President and CEO Chris Seiter - CFO Conference Call Participants Gary Nachman - BMO Capital Ami Fabia - SVB Leerink Annabel Sami - Stifel S...

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash Position Expected to Fund Operations into the First Half of 2022  NEW HAVEN, Co...

NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced th...

NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced th...

Thinly traded nano cap Trevi Therapeutics ( TRVI -17.7% ) is under modest pressure on turnover of only 27K shares in reaction to its announcement that, based on a recommendation from the independent Data Monitoring Committee (DMC), it will increase target enrollment to 360 from 240 in it...

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO ™ as Proposed Trade Name for Nalbuphine ER   NEW HAVEN, ...

The following healthcare companies have filed for mixed shelf offerings: More news on: Veru Inc., Cancer Genetics, Inc., Trevi Therapeutics, Inc., Healthcare stocks news, , Read more ...